CAS 1021950-26-4|Tyrosine kinase inhibitor

Introduction：Basic information about CAS 1021950-26-4|Tyrosine kinase inhibitor, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Tyrosine kinase inhibitor BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Tyrosine kinase inhibitor
CAS Number	1021950-26-4	Molecular Weight	586.61300
Density	/	Boiling Point	/
Molecular Formula	C₃₁H₃₁FN₆O₅	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	1-N'-(4-fluorophenyl)-1-N-[4-[[2-(2-morpholin-4-ylethylcarbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide
Synonym	More Synonyms

Tyrosine kinase inhibitor BiologicalActivity

Description	A Tyrosine kinase inhibitor.
Related Catalog	Signaling Pathways >>Protein Tyrosine Kinase/RTK >>c-Met/HGFRResearch Areas >>Cancer
References	[1]. Inoue T, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol. 2012 Aug 20;10(1):167. [2]. Bowen JM, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther. 2012 Nov 1;13(13). [3]. Sun FK, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl). 2012 Jun;125(12):2231-4. [4]. Thamm DH. Tyrosine kinase inhibitor special issue. Vet Comp Oncol. 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x. [5]. Eriksson A, et al. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer J. 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28.

Description

A Tyrosine kinase inhibitor.

Related Catalog

Signaling Pathways >>Protein Tyrosine Kinase/RTK >>c-Met/HGFRResearch Areas >>Cancer

References

[1]. Inoue T, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol. 2012 Aug 20;10(1):167.

[2]. Bowen JM, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther. 2012 Nov 1;13(13).

[3]. Sun FK, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl). 2012 Jun;125(12):2231-4.

[4]. Thamm DH. Tyrosine kinase inhibitor special issue. Vet Comp Oncol. 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x.

[5]. Eriksson A, et al. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer J. 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28.

Chemical & Physical Properties

Molecular Formula	C₃₁H₃₁FN₆O₅
Molecular Weight	586.61300
Exact Mass	586.23400
PSA	137.68000
LogP	4.38850
InChIKey	PKOVTRMHYNEBDU-UHFFFAOYSA-N
SMILES	O=C(NCCN1CCOCC1)c1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)ccnc2[nH]1
Storage condition	2-8℃

Synonyms

N-(4-fluorophenyl)-N'-(4-{[2-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1,1-cyclopropanedicarboxamide

cyclopropane-1,1-dicarboxylic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)quinolin-4-yloxy]phenyl}amide (4-fluorophenyl)amide

XL184-Supplied by Selleck Chemicals

S1119_Selleck

CS-0524

Tyrosine kinase inhibitor

Recommended......